ROR2-specific CAR T cells are effective against hematologic and solid tumors and well tolerated in mice

Receptor tyrosine kinase (RTK)-like orphan receptor 2 (ROR2) has been nominated as a target for kinase inhibitors due to its role in oncogenic signaling. Here, we show that ROR2 is a target for chimeric antigen receptor (CAR) T cells in hematologic and solid tumors. We show consistent ROR2 expression in multiple myeloma (MM) and developed ROR2-CAR T cells that confer potent activity against human MM xenografts in vivo. We analyzed public gene expression data and reveal an inverse correlation between ROR2 expression and patient survival for six types of cancer, i.e., lower-grade glioma, thyroid carcinoma, stomach adenocarcinoma, bladder cancer, and papillary and clear cell renal cell cancer (ccRCC). We confirm potent activity of ROR2-CAR T cells against ccRCC in vitro and in vivo. Treatment with ROR2-CAR T cells was well tolerated, without signs of on-target off-tumor toxicity in mice, supporting the role of ROR2 as an oncofetal antigen with utility for CAR T cell therapy.

Authors

Institutions

Publication Details

Journal
Cell Reports Medicine
Published
2025-10-01
DOI
https://doi.org/10.1016/j.xcrm.2025.102400
Citations
1
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
1.05
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

ROR2-specific CAR T cells are effective against hematologic and solid tumors and well tolerated in mice

Charis Kalogirou, Robert Klopfleisch, Thomas Nerreter, Michael Rade et al.
1 citations
Cell Reports Medicine
CAR-T cell therapy research
1.05
article

ROR2-specific CAR T cells are effective against hematologic and solid tumors and well tolerated in mice

Charis Kalogirou, Robert Klopfleisch, Thomas Nerreter, Michael Rade, Ulrike Koehl, Kristin Reiche, Sophia Danhof, Jörg Lehmann, Fabian Freitag, Christoph Rader, K. Martin Kortüm, Justus Weber, Laura Mainz, Josefine Michael, Mathias T. Rosenfeldt, Hermann Einsele, Liz Therese Tony, Claudia Mueller, Peter Spieler, Michael Hudecek
article en
1 citations

Abstract

Receptor tyrosine kinase (RTK)-like orphan receptor 2 (ROR2) has been nominated as a target for kinase inhibitors due to its role in oncogenic signaling. Here, we show that ROR2 is a target for chimeric antigen receptor (CAR) T cells in hematologic and solid tumors. We show consistent ROR2 expression in multiple myeloma (MM) and developed ROR2-CAR T cells that confer potent activity against human MM xenografts in vivo. We analyzed public gene expression data and reveal an inverse correlation between ROR2 expression and patient survival for six types of cancer, i.e., lower-grade glioma, thyroid carcinoma, stomach adenocarcinoma, bladder cancer, and papillary and clear cell renal cell cancer (ccRCC). We confirm potent activity of ROR2-CAR T cells against ccRCC in vitro and in vivo. Treatment with ROR2-CAR T cells was well tolerated, without signs of on-target off-tumor toxicity in mice, supporting the role of ROR2 as an oncofetal antigen with utility for CAR T cell therapy.

Cell Reports MedicineVol. 6(10)
Scripps Research Institute (US), University of Würzburg (DE), Universitätsklinikum Würzburg (DE), Fraunhofer Institute for Cell Therapy and Immunology (DE), Freie Universität Berlin (DE)
Openalex Percentile: Top 17%
CAR-T cell therapy research
1.05
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.